Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Molecular Partners AG focuses its patent prosecution within the Biotechnology & Pharmaceuticals technology area. The company currently manages 4 pending office actions across its portfolio. This workload is distributed among 4 distinct examiners, which indicates that each pending matter is being reviewed by a different individual. Furthermore, the portfolio is spread across 4 distinct art units, suggesting a broad range of technical subject matter within the biotechnology sector.
The busiest examiner for this portfolio is DUNN, LINDSAY MICHELLE, who is currently responsible for 1 busiest examiner pending office action. Because there are 4 pending office actions in total, this examiner handles only a portion of the overall active workload. Practitioners should be prepared to navigate 4 distinct examiners and 4 distinct art units, which requires a coordinated strategy to ensure consistency across different technical departments. The distribution of 4 pending office actions across 4 distinct examiners means that the company must address a variety of examination styles simultaneously within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (75%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| BERHANE, SELAM | 1 | 58.4% | +56.7% |
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
| BOESEN, CHRISTIAN C | 1 | 75.9% | +21.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554248 | NOVEL DARPIN BASED CD70 ENGAGERS | DUNN, LINDSAY MICHELLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18174086 | RECOMBINANT PEPTIDE-MHC COMPLEX BINDING PROTEINS AND THEIR GENERATION AND USE | BOESEN, CHRISTIAN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18281161 | NOVEL DARPIN BASED CD123 ENGAGERS | BERHANE, SELAM | — |
| 18267608 | RECOMBINANT CD3 BINDING PROTEINS AND THEIR USE | BRADLEY, CHRISTINA | — |
| 18174086 | RECOMBINANT PEPTIDE-MHC COMPLEX BINDING PROTEINS AND THEIR GENERATION AND USE | BOESEN, CHRISTIAN C | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1675 | 1 |
| 1654 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554248 | NOVEL DARPIN BASED CD70 ENGAGERS | DUNN, LINDSAY MICHELLE | 1644 | §102§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18281161 | NOVEL DARPIN BASED CD123 ENGAGERS | BERHANE, SELAM | 1675 | §112DP | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18267608 | RECOMBINANT CD3 BINDING PROTEINS AND THEIR USE | BRADLEY, CHRISTINA | 1654 | §102§112DP | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18174086 | RECOMBINANT PEPTIDE-MHC COMPLEX BINDING PROTEINS AND THEIR GENERATION AND USE | BOESEN, CHRISTIAN C | 1684 | §102§112 | Non-Final OA | — | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial